BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to focus on his role as chairman and CEO of Walking Fish Therapeutics Inc. , a cell therapy...
BC Extra | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
BC Innovations | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BC Extra | Oct 10, 2019
Company News

bluebird tech to jump-start Novo in gene editing for hemophilia

A deal with bluebird bio is the latest move in Novo Nordisk’s push to remake its R&D, this time by partnering to develop a gene therapy for hemophilia A. The deal comes as sales for...
BC Extra | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1...
BC Extra | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
Items per page:
1 - 10 of 474
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to focus on his role as chairman and CEO of Walking Fish Therapeutics Inc. , a cell therapy...
BC Extra | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
BC Innovations | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BC Extra | Oct 10, 2019
Company News

bluebird tech to jump-start Novo in gene editing for hemophilia

A deal with bluebird bio is the latest move in Novo Nordisk’s push to remake its R&D, this time by partnering to develop a gene therapy for hemophilia A. The deal comes as sales for...
BC Extra | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1...
BC Extra | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
Items per page:
1 - 10 of 474